Selective VEGFR inhibitor improved survival in multi-regional study; regulatory submission started in U.S., other markets to follow

The acquisition fits squarely in Takeda’s transformation from a small molecule company to one built on multiple modalities. 

Yescarta became the second approved CAR T therapy in Japan, joining a basket of new approvals by the country’s Ministry of Health, Labour and Welfare. The therapy, developed by Gilead Sciences

Why Takeda says Shire accelerates execution of Weber’s globalization strategy

How Takeda is using external innovation to access new modalities